Physician profile
Hassan M Bitar
NPI 1699724450
$11,678.32
in general payments reported to CMS, 2019-2025
54 companies · $1,588 in 2025
The $1,588 reported for 2025 was more than what 90% of Neuromusculoskeletal Medicine & Omm providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,425 · 2020: $1,147 · 2021: $1,549 · 2022: $1,648 · 2023: $1,910 · 2024: $2,412 · 2025: $1,588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,843 · Education: $66.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,843.16 |
| Education | $66.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,734.38 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Ucb, INC. | $1,038.47 | 2019-2025 | Briviact, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $1,017.99 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Pfizer INC. | $984.40 | 2019-2025 | |
| Amgen INC. | $734.27 | 2019-2022 | |
| Allergan, INC. | $555.00 | 2019-2022 | |
| Lundbeck LLC | $534.38 | 2021-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $472.83 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Scilex Pharmaceuticals INC. | $426.39 | 2019-2024 | Ztlido |
| Neurocrine Biosciences, INC. | $321.95 | 2023-2025 | Ingrezza, Ongentys |
| Sunovion Pharmaceuticals INC. | $264.58 | 2019-2022 | |
| Biogen, INC. | $255.58 | 2019-2024 | Skyclarys |
| Emd Serono, INC. | $244.01 | 2019-2024 | Mavenclad |
| Eisai INC. | $236.73 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $216.47 | 2019-2020 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hassan Bitar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.